Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database.
OBJECTIVE
Weight loss in patients with type 2 diabetes can improve glycemic control, lower blood pressure, and improve dyslipidemia. Glucagon-like peptide (GLP-1) receptor agonists are associated with weight loss and have potentially beneficial effects on cardiovascular risk biomarkers; however, there is limited information to indicate whether these effects remain outside of clinical trials.


METHODS
Medical records from the General Electric Centricity research database were analyzed retrospectively to evaluate the relationship between weight loss and glycemic control and changes in blood pressure and lipids in patients with type 2 diabetes initiating therapy with exenatide, sitagliptin, or insulin. Baseline and follow-up (90-365 days after the index date) for weight, A1C, fasting blood glucose (FBG), blood pressure, triglycerides, and LDL, HDL, and total cholesterol were assessed.


RESULTS
A total of 6,280, 5,861, and 32,398 patients receiving exenatide, sitagliptin, or insulin, respectively, were included in the analysis. Exenatide-treated patients lost a mean +/- SD of 3.0 +/- 7.33 kg, sitagliptin-treated patients lost 1.1 +/- 5.39 kg, and insulin-treated patients gained 0.6 +/- 9.49 kg. There was a significant association between weight loss and a reduction in A1C and FBG with exenatide only and a reduction in blood pressure for all therapies. Weight loss was associated with some improvements in lipids, primarily in the GLP-1 receptor agonist group, with little association in the insulin group.


CONCLUSIONS
Weight reduction with GLP-1 receptor agonists was associated with a shift toward a more favorable cardiovascular risk profile. Outcome trials are needed to determine whether improvement in biomarkers translates into a reduction in cardiovascular events in patients with type 2 diabetes.
Horton
Edward S
ES
Joslin Diabetes Center, Boston, Massachusetts, USA. edward.horton@joslin.harvard.edu
Silberman
Cheryl
C
Davis
Keith L
KL
Berria
Rachele
R
D000368:Aged; D001786:Blood Glucose / Q000187:drug effects; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D000077270:Exenatide; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010455:Peptides / Q000627:therapeutic use; D011719:Pyrazines / Q000627:therapeutic use; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000627:therapeutic use; D014688:Venoms / Q000627:therapeutic use; D015431:Weight Loss / Q000502:physiology*
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D010455:Peptides; D011719:Pyrazines; D014230:Triazoles; D014688:Venoms; D000077270:Exenatide; D000068900:Sitagliptin Phosphate
Diabetes Care. 2005 Apr;28(4):888-94
15793191
Curr Med Res Opin. 2007 Sep;23(9):2157-69
17669232
Int J Obes Relat Metab Disord. 2002 Aug;26(8):1046-53
12119569
Lancet. 1998 Sep 12;352(9131):837-53
9742976
Diabetes Care. 1998 Jan;21(1):87-92
9538975
Curr Med Res Opin. 2008 Jan;24(1):275-86
18053320
Diabetes Obes Metab. 2006 Jul;8(4):436-47
16776751
Am J Med. 2009 May;122(5):443-53
19375554
Diabetes Care. 2007 Jun;30(6):1562-6
17372155
Clin Ther. 2007 Jan;29(1):139-53
17379054
Nat Rev Endocrinol. 2009 May;5(5):262-9
19444259
Diabetes Care. 2008 Oct;31(10):1960-5
18697899
Lancet. 2006 Nov 11;368(9548):1696-705
17098089
Diabetes Care. 2006 Dec;29(12):2632-7
17130196
Diabetes Care. 2000 Oct;23(10):1499-504
11023143
Diabetes Care. 2007 Jun;30(6):1374-83
17363746
Int J Obes Relat Metab Disord. 1992 Jun;16(6):397-415
1322866
Diabetes Care. 2007 Aug;30(8):1979-87
17485570
Diabetes Care. 1997 Nov;20(11):1744-66
9353619
J Intern Med. 2006 Mar;259(3):314-22
16476109